Charts: Energy and Global Banks

 

“Our analysis leads us to believe that recovery is only sound if it does come from itself. For any revival which is merely due to artificial stimulus leaves part of the work of depression undone and adds, to an undigested remnant of maladjustments, new maladjustments of its own.” — Joseph Schumpeter (1883—1950)

 

Oil and Energy Stocks Disconnect

 

For the one-month period ended 23 April, the front-end WTI crude futures contract is down 29.4 per cent. Concurrently, the Energy Select Sector SPDR Fund $XLE is up 46.5 per cent. A delta of 75.9 per cent. Quite the disconnect, or so it seems anyway.

oil

(As the major holdings within $XLE are that of oil majors such as Exxon and Chevron, it serves as a fairly good proxy for the performance of the US oil majors.)

The thing about oil majors is that they generate a very small portion of their value from the barrels of crude they sell any given day; or any given month, for that matter. Rather, the vast majority of their value is derived from their respective reserves i.e. the estimated amounts of crude they hold underground.

oil2

While all headlines are about the crash in front month prices, back-end prices have risen. Back-end prices are up more than 15 per cent over the last month. That is, what the oil majors hold in the ground has become more valuable even as selling prices today are lower. Since, the value of reserves far exceeds the value derived from near-term cash flows, oil major stocks are up even as spot crude prices are down.

 

Global Banking

 

“The process by which banks create money is so simple that the mind is repelled. When something so important is involved, a deeper mystery seems only decent” — John Kenneth Galbraith (1908—2006)

 

The below chart is of the relative performance of US, European and Japanese banks relative to their respective broader market indices. (All three ratios have been indexed to 100 at the start of the time series.)

banking

Shareholders in banks, be it in the US, Europe or Japan, have not had the greatest run. In hindsight, one the keys to outperforming broader market indices since the Global Financial Crisis would have been to simply avoid banks.

On a shorter-term time frame (say 3 to 18 months), capital markets are largely driven by the ebbs and flows of liquidity. That is, in Benjamin Graham’s parlance, market behave much like voting machines in the short-term. While on a longer-term timeframe, markets come to reflect the underlying fundamental conditions of the economy, sector and specific company. That is, markets behave much like weighing machines over the long-term.

Given the prolonged under performance of banks, across major global markets, suggests the market has ‘snuffed out’ that there are real issues plaguing the global banking system. To circle back to the Schumpeter quote at the very beginning of the piece, the global banking revival has been “merely due to artificial stimulus” which has left “part of the work of [recession] undone”. That is, after one extraordinary policy measure after another, the global banking system has been surviving on “artificial stimulus” rather undergoing a wholesale recovery.

 

Why is that?

 

A few weeks ago, we outlined the Eurodollar system and how its inability to grow was translating into the relative under performance of the rest of the world versus the US. In that piece, we identified a time series published by the Bank for International Settlements, as a suitable proxy for determining the size of the Eurodollar system. With the aid of the below chart, we take that discussion a step further this week.

banking2

In the above chart, the Eurodollar proxy is plotted against, another time series provided by the Bank for International Settlement — global over-the-counter (OTC) derivatives outstanding, using notional not netted amounts.

A quick primer on OTC derivatives. An investment bank writes a swap or OTC derivative — essentially a form of speculation being undertaken by a client – say for a notional long position exposure on US dollar 1 billion in US Treasuries. The bank might require US dollars 25 million in cash or collateral to be posted as margin. (Using the Eurodollar deposits as the ‘margin’, suggests the collateral is typically between 2 and 5 per cent of notional amounts outstanding.)

The Global Financial Crisis and the subsequent regulations that were implemented in its aftermath brought to a halt the meteoric rise in OTC derivatives issued by investment banks. This in turn has stalled the growth in Eurodollar deposits. Moreover, since writing OTC derivatives was a high margin activity for investment banks, returns on invested capital generated by banks have collapsed.

The risk we worry about is that of one or more of the global banks are holding on to a ticking time bomb in their derivative books. For the central banks and regulators have stalled the growth of OTC derivatives but amounts outstanding remain in the vicinity of where they were just before the crisis.

For banks to start out performing broader indices, we think there needs to be either a flushing out of the risks in their derivative books — which no central bank or private sector bank would willingly allow — or a loosening of the regulations, which is simply another way to kick the can down the road. Neither choice is palatable, we suspect. Meaning that it will take a crisis that upends the current banking system and starting afresh to bring life back to the banking sector.

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

The Lay of the Land

Premium Content: Discussion of the regime shift caused by the Fed’s recent announcements

“International big business has made revolutions before now to safeguard its interests. At one time it made them … in the name of Liberty, Equality and Fraternity. Now, with Socialism to fight, it makes them in the name of Law and Order and Sound Finance. Assassination? If an assassination is going to be good for business, then there will be an assassination.” — Eric Ambler, The Mask of Dimitrios

Earnings Yield to 10-Year Treasury Yield

The ratio of S&P 500 earnings yield (earnings divided by price) to the 10-year Treasury yield, at the end of March, was at its highest level since 1949.

1

The year 1949 was a great time to invest in the stock market, as the market bottomed in June thereupon began one of the greatest bull markets in US history.

The US equity market was, however, trading at a trailing price-to-earnings multiple of 6.6x and 10-year treasury yields were 2.3 per cent. The challenge faced by long-term investors and asset allocators today is the S&P 500 is trading above 20x trailing earnings and long-terms yields are below 1 per cent.

Of course, as we have discussed in recent weeks, shifts in market structure make valuation metrics, relative or absolute, broadly speaking, unsuitable for temporal comparisons that stretch across multiple market regimes. Rather, valuation metrics are best used as an investment decision making tool when markets are mean-reverting. That is, valuations are most suitable for comparisons within individual market regimes but not across them.

The Lay of the Land

The Federal Reserve by announcing its decision to purchase exchange traded funds that buy high-yield debt, which sparked the biggest rally in junk bonds in more than a decade, has instituted a regime change.

The Fed’s balance sheet will begin to creep into lower and lower rungs of the corporate capital structure. Eventually crowding out private capital by outbidding on price first (i.e. lowering yields below the point of economic profit) and then by becoming the only game in town.

Private capital, other than that mandated or regulated (read: forced) to participate, will first exit the investment grade market and then the high yield market. The question then is, where will private capital be re-directed. The answer is probably more of the same: stocks, leveraged buyouts, growth equity and venture capital. For liquid market participants, occasional bouts of volatility notwithstanding, we may soon enter a phase where the adage of ‘there is no alternative’, or more colloquially TINA, once again becomes the reason to be long stocks.  

Away from capital markets, the economic impact of the decisions made by the Fed and the US Treasury may prove to be even more weighty.

The Fed’s decision to, in effect, backstop the investment grade and junk bond markets will almost definitely entice the assumption of ever greater amounts of leverage by corporations — even though businesses as a whole are already over leveraged. Second, in an environment where the once financial truths of the time value of money and credit risk have been suspended, there will be further misallocation of capital away from productive activities to financial engineering. Lastly, with independent workers and smaller enterprises lacking the staying power and the captive legal expertise to navigate bail-out claims, the biggest benefactors of this crisis will be entrenched “big business”. This will, we think, further the sense of inequality as losses are once again socialised and profits remain the privilege of the very few.

We neither mean to pontificate nor to bemoan the realities. Our intention is to describe the lay of the land so that we be better placed to navigate markets.

COVID-19 Virulence

2

The above chart, in log scale, is of the aggregate confirmed cases of COVID-19 in the US, UK, Sweden, Brazil, India and New York State.

Obviously, we are not epidemiologists and do not want to pretend to be either. Some points are worth noting, however.

First, be it because testing for the virus is increasing linearly, social distancing measures are working or the COVID-19 is not as virulent as feared, the increase in confirmed cases is no longer increasing exponentially. Of particular note is the flatlining in New York State, hitherto the epicentre of the pandemic in the US.

Second, unless there is systematic underreporting of cases, the trajectory of confirmed cases in Sweden, which has not enacted social distancing measures, suggests that the widespread ‘closure’ of economies may not have been necessary.

Lastly, presupposing no systematic underreporting, the virulence of COVID-19 is proving to be lower in the warmer climes of Brazil and India. If so, as we head into the summer months, there remains hope of a sharp drop off in the spread of the virus. That being said, this also raises the prospect of another wave of cases come the winter.

Ignoring for the moment the potential revival in the winter, if the summer months bring reprieve and confirmed cases peak globally during April, the probability of the S&P 500 re-testing the year-to-date lows is likely to be much lower than anticipated by most. Moreover, with plenty of cash on the side lines, the path of least resistance for stocks may be higher, much higher.

Two Charts

We end this week’s piece with two charts.

Chinese ADRs Outperformance

3

The above chart compares the price performance of a select few Chinese ADRs trading in the US versus that of the S&P 500 Index and the NASDAQ 100 Index. The Chinese ADRs, we highlight, have significantly outperformed the broader indices and even many of the leading big tech stocks. The only big tech name with comparable performance to most of these ADRs is that of Amazon.

This warrants further digging into Chinese tech plays at some point soon.

Gold-to-Oil Ratio

4

The below chart is of the gold-to-oil ratio, using Brent crude spot prices. (The dashed lines are the one and two standard deviation points above and below the average of the ratio, which is shown with the black line.)

The fortunes of the two commodities could not be starker. This chart is not so different from the earnings yield to treasury yield chart at the start of the piece.

We are in truly unique times. There will come a time to be long oil, short gold.

Thank you for reading!

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Existential Crisis in Europe: Through the Lens of Healthcare

 

“Like Hitler, like Stalin, the énarque believes that power will always prevail over economics.” ― Bernard Connolly, The Rotten Heart of Europe: Dirty War for Europe’s Money

“Everybody aspires to an affordable home, a secure job, better living standards, reliable healthcare and a decent pension. My generation took those things for granted, and so should future generations.” ― Jeremy Corbyn

 

Señor Mario Draghi pledged in 2012 to do “whatever it takes” to save Europe from the sovereign debt crisis that engulfed many members of the European Union. Those momentous words took the eurozone out of the throes of a crisis and put into motion an epic collapse in bonds yields in Europe first, the rest of the developed world second.

 

Mario Draghi’s resolve brought about an immediate shift in the market’s mood. Traders reacted with alarming speed, jumping into European sovereign bonds, reaping huge rewards as yields collapsed across the Eurozone. Mario Draghi understood well the importance of psychology on market participants when he stepped up to avert the EU’s existential crisis.

 

Today, the European Union faces a different kind of existential crisis. One brought on by healthcare systems in Italy, Spain and other parts of Europe bursting at the seams, unable to provide the necessary care to contain the suffering of those afflicted with the coronavirus.

The physical world is defined by constraints. Neither words nor policy can be used to conjure up more hospital beds, deliver vaccines or transform able citizens into frontline healthcare professionals. Yes, war time like measures can be taken to divert productive resources away from the expendable to the essential, even such measures, however, require time, energy and a requisite set of skills and resources.

Words are unlikely to suffice this time around.

 

Europe Divided

 

“Italy’s political leaders from Left to Right have erupted in fury over the EU’s minimalist, insulting, and cack-handed response to the Covid-19 pandemic, warning that lack of economic solidarity risks pushing the bloc’s festering divisions beyond the point of no return.” ― Ambrose Evans-Pritchard, EU project in ‘mortal danger’ if Italy and Spain are abandoned

 

Jean Monnet, one of the founding fathers of the European Union, famously argued that “Europe will be forged in crises, and will be the sum of the solutions adopted in those crises.”

The COVID-19 pandemic has revealed the fragility of the bond that holds the EU together. In a matter of weeks, the EU has gone from a single bloc to each member fending for themselves in a bid to contain the damage wrought by the pandemic.

France, Italy, Spain and six other members of the EU, in a joint letter to European Council president Charles Michel, have called for the issuance of ‘coronabonds’ — that is, joint European debt to finance the fight against coronavirus. Germany and the Netherlands, in response, have expressed reservations and are ruling out any such issuance.

The Europe Union has not put forth a solution to the current crises, will the consequence be a continent divided?

 

Currency Straitjacket

 

EU membership comes with many constraints. Particularly onerous are the budgetary limitations placed on those economies unable to live within their means or suffering from an economic slowdown. Further exacerbating the issue is the common currency, which has eliminated the flexibility to depreciate previously availed by the economic laggards remain competitive.

Take for instance, the ratio of the purchasing power parity (PPP) based exchange rates for Germany and Italy. (In the chart below, a downward sloping line implies a depreciation of Italy’s exchange rate relative to Germany’s exchange rate in PPP terms.)

PPP Germany Italy

During the 1990’s, the Italian lira almost consistently depreciated relative to the deutschemark. This process of continuous depreciation enabled the Italian economy to compete with the German economy, if not in terms of sophistication, most definitely in terms of price. Since the introduction of the euro, however, Italy has lost this flexibility and can improve upon the German offering neither in price nor in sophistication.

This lack of flexibility combined with the budgetary and fiscal constraints that come with EU membership, is unlikely to escape the scrutiny of the Italians and their Mediterranean neighbours. Especially as they come to weigh the costs of EU membership in shadow of the suffering of their citizenry during the COVID-19 pandemic. The evidence is particularly damning, when one considers how these constrictions have translated into systematic underinvestment in the healthcare systems of countries that have lagged behind economically.

 

Healthcare Expenditure

 

The chart below compares healthcare expenditure, as a share of total government expenditure for Germany, Italy and Spain.

Healthcare Exp pct

Healthcare spending, relative to other forms of government spending, in Germany has increased by almost 2 percentage points between 2010 and 2019. Whereas it has declined by 1 percentage point in Italy and remained about the same in Spain.

In both absolute and relative terms, this has translated into a significant increase in the amount Germany spends on healthcare. In 2010, Germany spent, in current euro terms, approximately €60 billion more than Italy on healthcare. In 2019, the difference in healthcare expenditure between the two nations amounted to more than €120 billion. In per capita terms, Germany spent 9.2 per cent more than Italy on healthcare in 2010; in 2019, the difference was 46.3 per cent.

Given its robust economic performance, Germany, within the confines of the EU’s rules, has been able to substantially increase its government expenditures. Whereas, Italy and Spain, in the aftermath of the sovereign debt crisis, have been unable to increase overall government expenditure. The unfortunate corollary of which is a stagnation of investment in their respective healthcare systems.

Healthcare Exp abs

The growing disparity in healthcare investment across the EU is even more stark when comparing the availability of hospital beds. In 1995, Italy had 6.3 beds per 1,000 people, Spain 3.9 and Germany 9.7. At the end of 2017, Italy was down to 3.2 beds per 1,000 people, Spain 3.0 and Germany 8.0.

hospital beds

Italian and Spanish hospital bed capacity per capita has declined by half and one third, respectively, even as their populations have aged and the need for healthcare services has increased not decreased.

 

A New Way Forward

 

Whether it is German conservatism, Mediterranean profligacy or a combination of both that has contributed to the woeful under investment in healthcare in Spain and Italy, we do not know for certain. We do, however, see the statistics as a powder keg that could bring about the end of EU in its current form.

For the populace may withstand economic hardship in pursuit of a lofty goal; there are few, however, that will accept the suffering or loss of loved ones. If they are not already, it is only a matter of time before Italians and Spaniards begin questioning why they given up sovereignty over their laws, their borders, their budget and their currency, when in their time of need their membership in the EU has hindered, not supported, them.

From Arundhati Roy in the Financial Times:

 

“Historically, pandemics have forced humans to break with the past and imagine their world anew. This one is no different. It is a portal, a gateway between one world and the next.

We can choose to walk through it, dragging the carcasses of our prejudice and hatred, our avarice, our data banks and dead ideas, our dead rivers and smoky skies behind us. Or we can walk through lightly, with little luggage, ready to imagine another world. And ready to fight for it.”

 

The European experiment, once these trying times pass, may ultimately hinge upon which nation chooses to walk into the future lightly. Will it be one of Italy, Spain or any one of the other member nations suffering under the weight of the euro, choosing to leave behind the currency? Or will Germany overcome the scars of her past and shed its fiscal conservatism?

Time will tell. For now, we believe the Europe of tomorrow, will be unlike the Europe of yesterday.

 

Stay safe.

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

War Like Symptoms

 

“We have now sunk to a depth at which restatement of the obvious is the first duty of intelligent men.” ― George Orwell

 

A comment about China’s manufacturing PMI for March before getting to this week’s update.

 

China’s manufacturing PMI for March came in unexpectedly strong at 52.0, after recording 40.3 in February and above consensus expectations of 42.5. The kneejerk reaction to this data point from a number of market commentators was that China, once again, was fudging its economic data.

 

The thing about a kneejerk reaction is that it is an emotional response, one that has not been clearly thought through. And indeed, if one considers (a) the PMI is a diffusion index and (b) the statement from Foxconn, the world’s largest provider of electronics manufacturing services, at the start of March suggesting that their Chinese operations should return to normal during the month, the manufacturing PMI coming in at 52.0 is somewhat unsurprising.

 

The PMI is a diffusion index based on the number of companies reporting an improvement or deterioration in business activity relative to the previous month. A reading little above 50 suggests that slightly more than half of the companies indicated an improvement in activity relative to February’s historic lows. A much higher reading would have been required to suggest that manufacturing activity is back to normal in China.

 

Anecdotally, in February we contacted a sample of small and medium Chinese manufacturers through Alibaba and found that all were closed for business. We contacted the same sample of manufacturers again in mid-March and found that they were all up and running and accepting orders.

 

Armed with data and the correct definitions, a lot of noise can be filtered out.

 

On to the update.

 

War Like Symptoms

 

President Lyndon Johnson declared a war on poverty. President Richard Nixon declared a war on drugs. And last month President Donald Trump described the battle to slow the spread of COVID-19 as “our big war.”

 

Whether it is a war or not is a matter of debate. US public debt, as a percent of GDP, is, however, started to exhibit war like symptoms even before the passing of the largest stimulus package in US history. When it is all said and done, the US’s debt-to-GDP ratio will have blown out the levels hit during and in the immediate aftermath of World War II.

US debt.png

Modern Monetary Theory is here in everything but name.

 

From the Wall Street Journal (emphasis added):

 

“With 20% of Americans locked in their homes, nearly all air travel canceled, and the global supply chain disrupted, you don’t need to be a Keynesian to think the government should intervene. But that doesn’t mean the Cares Act—an acronym for Coronavirus Aid, Relief, and Economic Security—is wise. The last thing we need at this moment is a Keynesian stimulus. Since the lockdowns constrain supply, stimulating demand would lead only to a rise in prices.

 

As the purveyor and custodian of the global reserve currency, the US effectively has an ‘elastic currency’, the circulation of which can expand and contract to meet the needs of economic activity. Whether the expansion or contraction leads fluctuations in price levels depends on whether the demand for US dollar liquidity is sufficiently keeping pace with the supply of US dollar liquidity.

 

Pricing conditions, that is inflationary or deflationary pressures, are primarily a function of the spread between the supply and demand of US dollar liquidity. A condition of excess liquidity exists when there is a greater supply of US dollar liquidity than there is demand for it, gives rise to inflationary pressures. When there is an insufficient supply of US dollar liquidity relative to demand, an economy is beset by deflationary pressures.

 

So, the creation of a large amount of liquidity in an economic system is not immediately inflationary — rather, if the expansion in liquidity occurs in tandem with an expansion in economic activity, then it can facilitate continued expansion of the economy.

 

From the Bank for International Settlements on 1 April 2020 (emphasis added):

 

“On the demand side, institutional investors (insurers, pension funds and other portfolio asset managers) play a key role. Such investors have obligations in domestic currency, but they hold a globally diversified portfolio, with a substantial portion denominated in the US dollar.  To finance the purchase of dollar assets, they swap domestic currency into dollars, thereby gaining access to dollar funding on a currency-hedged basis. Their portfolios have grown substantially since the GFC, giving rise to greater hedging needs.

 

On the supply side, dollars are provided by banks and other financial intermediaries, who source their dollars in global capital markets. However, in the decade following the GFC, banks that provide such hedging services have become a smaller part of the overall financial system, reflecting narrowing lending margins due to low interest rates, as well as tighter regulation (Erik et al (2020)).

 

Against this backdrop, the financial turbulence of recent weeks has led to a sharp decline in the supply of hedging services by banks as they retrench in the face of the shock. In addition, banks have experienced drawdowns of credit lines from corporate borrowers, which have crowded out other forms of lending by banks. Prime money market funds that traditionally supply dollar funding have experienced redemptions, leading to thinner supply. Together, the pullback in the supply of dollars from banks and market-based intermediaries (even as dollar demand has remained high) has resulted in the sharp increase in indicators of dollar funding costs.

 

Financial intermediaries are stepping away from their core activities. Thereby circumventing the flow of liquidity in the monetary system despite the Federal Reserve and US Treasury’s best efforts to flush the system with dollars. Supply of dollars is falling short of demand. Outside of pockets of price gouging and price spikes for specific highly demanded goods, the probability of a spike in inflation remains low.

 
The below is a chart of four-quarter moving average of the Citi Macro Risk Index versus the year-over-year change non-residential fixed investment by the private sector in the US. (A rising magenta line implies declining macro uncertainty while a rising line implies increasing macro uncertainty.)

 

Nonresi fixed inv.png

 

Non-residential fixed investment declines during periods of macroeconomic uncertainty.

 

Given that we are in a period of extremely high levels of uncertainty, capital investment by the private sector is likely to remain low — ergo production capacity utilisation in the economy will remain low. Without low levels of unemployment and high levels of capacity utilisation, inflation is unlikely to manifest. Unless of course one expects a complete loss of faith in the US dollar hegemony — something we do not perceive as a near-to-medium term risk.

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Vertex Pharmaceuticals $VRTX

 

Investment Case

 

  • Vertex Pharmaceuticals is the only pharma company with the necessary regulatory approvals to market medicines for the treatment of cystic fibrosis, i.e. a sub-category monopoly.

 

  • Four approved medicines — TRIKAFTA SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO — with list prices ranging from $272,000 to $311,000 per annum

 

  • Across the US, Europe, Canada and Australia there are an estimated 75,000 patients with CF

 

  • Vertex’s medicines are presently being used to treat 60% of these patients; in the US, 90% of all CF patients are eligible for at least 1 out of Vertex’s 4 CF treatments

 

  • TRIKAFTA approved by the FDA for people 12 years or older and certain types of CF conditions in October 2019

 

  • Increasing the addressable market for Vertex’s medicines in the US by c. 6,000 patients.

 

  • Added $420m in additional revenue in 9 weeks since approval. TRIKAFTA is Vertex’s most successful launch and one of the most successful drug launches in the last 5 years.

 

  • Vertex has applied for marketing approval for the treatment in Europe.

 

  • Vertex reached deals with the Scottish government (September 2019) and NHS England (October 2019) to make ORKAMBI available.

 

  • Increasing the addressable market for the treatment by 5,350 patients. Minimal revenue in 2019 following the approvals. Management expects strong uptake in 2020.

 

  • In December 2019, the approval for KALYDECO in the European Union was expanded to include infants 6 to less than 12 months in age.

 

  • Strong revenue growth in 2020 driven by (1) TRIKAFTA in the US, (2) ORKAMBI in the UK and (3) the expanded approval for KALYDECO in the EU

 

  • TRIKAFTA contributed more than 10% of sales in 2019 despite only being available for 9 weeks and that too only in the US.

 

  • TRIKAFTA is expected to generate $1.3bn in sales in 2020. All else being equal, that would amount to year-over-year revenue growth of 21%.

 

  • For ORKAMBI assuming an up take by 60% of patients in England and Scotland at a discounted price of $125,000 per annum in 2020 would contribute top line growth of almost 10%.

 

  • Given the above, consensus estimate of 32.5% revenue growth in 2020 may prove to be low.

 

  • Upside risks arising from (1) approval of TRIKAFTA in Europe, Canada and Australia and (2) positive outcomes from clinical trials to expand the treatment’s approval to include patients ages 6 to 11.

 

  • Strong balance sheet — no debt, net cash position of $3.8bn; high levels of cash generation — average free cash flow generation of $1.1bn per annum over last three years

 

Key Risks

 

  • Sales of Vertex’s products depend, to a large degree, on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations.

 

  • Third-party payors are becoming stricter in the ways they evaluate medical products and services and the containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort.

 

  • The market for drugs that treat CF is currently a monopoly: Vertex owns the rights to the only medicines with marketing approval in the US, Europe, Canada and Australia that treat the rare condition.

 

  • In October 2019, Arrowhead Pharmaceuticals Inc. presented preclinical data at the 2019 North American Cystic Fibrosis Conference on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis.
    • Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies.
    • Further progress by Arrowhead, or any other competitor for that matter, in developing treatments for CF are likely to weigh on Vertex’s share price

 

  • In 2019, Vertex began a Phase 2 clinical trial evaluating VX-814 as a potential treatment for AAT deficiency and initiated a Phase 1 clinical trial evaluating VX-864 — a second investigational small molecule corrector for the treatment of AAT deficiency.

 

  • Arrowhead, with its lead drug ARO-AAT, is further ahead of Vertex in developing a treatment for AAT deficiency.Arrowhead’s stock was punished due to Vertex’s progress with VX-814. There could be a reversal of fortunes should Arrowhead’s drug moves further along the FDA’s approval process.

 

  • Given the crossover, rumours of Vertex acquiring Arrowhead have surfaced on several occasions.

 

  • Arrowhead’s market is only ~3.7bn versus Vertex’s ~63bn, the dilution for Vertex shareholder is likely to be limited. Nonetheless, in the event of an acquisition, it could prove to be a short-term headwind to Vertex’s share price.

 

  • Vertex has a partnership with CRISPR to develop treatments for DMD and DM1, which cost the company $175m upfront and potentially up $825m more

 

  • Vertex’s acquisition of Exonics required committing to a contingent liability of $755 million in milestone payments, i.e. if Exonics achieves certain milestones, Vertex will have to make further payments to the shareholders of Exonics at the time of acquisition

 

Company Overview

 

  • Vertex develops treatment regimens for patients with cystic fibrosis (CF).

 

  • CF is a hereditary disease that mainly affects the lungs and digestive system, but it can result in fatal complications such as liver disease and diabetes. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas.

 

  • CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span. There is no cure for the condition, but good nutrition and taking steps to thin mucus and improve mucus expectoration are said to help.

 

  • Vertex obtained approval for TRIKAFTA — the first triple combination regimen for CF — in October 2019. The drug is approved by the FDA for people 12 years or older and certain types of CF conditions — the company estimates that the approval increases number of patients eligible for Vertex’s medicines in the US by c. 6,000.

 

  • The company is working to obtain approval for the drug in ex-US markets and has already submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).

 

  • List price for TRIKAFTA is $24,000 per 28-day pack (or $311,000 per annum).

 

  • From FDA’s approval on 21 October through year-end, Vertex recorded $420 million in revenue from the drug. Making it the best launch of Vertex’s CF treatments and one of strongest starts for a new drug in the US in the past five years.

 

  • As a result, 4Q2019 revenues came in at ~5x higher than consensus estimates.

 

  • Vertex’s marketed medicines, in addition to TRIKAFTA, are SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.

 

  • Approximately 90% of all CF patients in the US are eligible for Vertex’s medicines. The company’s R&D efforts are focused on pursuing other therapeutic approaches to address the remaining 10% of CF patients.

 

  • The company’s four medicines are estimated to treat approximately 60% of the c. 75,000 CF patients in North America, Europe and Australia.

 

  • Vertex reached deals with the Scottish government (September 2019) and NHS England (October 2019) to make ORKAMBI available.

 

  • In Scotland, an estimated 350 patients are eligible for the drug, which has a list price of more than £100,000 per annum.

 

  • While in England, 5,000 children and young adults suffering from CF are now eligible for the drug. (The prices agreed between Vertex and the two parties have not been disclosed.)

 

  • According to the company’s chief commercial officer, during the 4Q2019 earnings call, the two deals did not materially impact revenues during 2019. The company, however, expects revenue from the European market to ramp up in 2020.

 

  • In June 2019, the FDA expanded the approval for SYMDEKO/SYMKEVI to include CF patients 6 to 11 years old.

 

  • The medicine was originally approved in February 2018 for CF patients 12 years old and older. This was Vertex’s third medication to be given marketing authorization.

 

  • An application was submitted to the EMA in 4Q2019 to expand the approval for Europe to include children 6 to 11 years of age.

 

  • The list price for the medicine is $292,000 per annum.

 

  • In April 2019, the FDA expanded the approval for KALYDECO to treat infants 6 to less than 12 months of age

 

  • KALYDECO is the first and only drug eligible for treating infants as early as 6 months of age.

 

  • In December 2019, the approval in the European Union was expanded to include infants 6 to less than 12 months in age.

 

  • The list price for the medicine is $311,000 per annum.

 

  • The company’s strategy includes actively seeking to acquire businesses and technologies needed to advance research in its areas of therapeutic interest as well as to access needed technologies.

  

Acquisitions

 

  • Acquisition: Exonics Therapeutics $245m, Jun 2019

 

  • Exonics is engaged in the development of gene editing therapies to treat severe genetic neuromuscular diseases, including Duchenne muscular dystrophy (DMD)

 

  • Acquisition added gene editing intellectual property, technology and expertise to Vertex.

 

  • Up to $755 million in milestone payments to selling shareholders if future development and regulatory milestones are met for certain programmes.

 

  • Acquisition: Semma Therapeutics $950m, Sep 2019

 

  • All-cash deal

 

  • Semma Therapeutics focuses on using stem cell-derived human islets as a possible cure for type 1 diabetes.

 

Research & Development

 

  • In addition to continuing research to identify additional drug candidates for the treatment of CF, Vertex is also focusing its R&D efforts on developing products for the treatment of serious diseases including AAT deficiency, APOL1-mediated FSGS, pain, sickle cell disease, beta thalassemia, DMD, DM1 and type 1 diabetes.

 

  • Alpha-1 Antitrypsin (AAT) Deficiency

 

  • A condition in which the body does not make enough of AAT, a protein that protects the lungs and liver from damage. The condition can lead to chronic obstructive pulmonary disease (COPD) and liver disease.

 

  • In 2019, the company began a Phase 2 clinical trial evaluating VX-814 as a potential treatment for AAT deficiency and initiated a Phase 1 clinical trial evaluating VX-864 — a second investigational small molecule corrector for the treatment of AAT deficiency.

 

  • Arrowhead Pharmaceuticals, with its lead drug ARO-AAT, is further ahead of Vertex in developing a treatment for AAT deficiency.

 

  • APOL1-Mediated Kidney Diseases

 

  • Focal segmental glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.

 

  • Apolipoprotein L1 is a protein that in humans is encoded by the APOL1 gene.

 

  • Inherited mutations in the APOL1 gene play a causal role in the biology of FSGS as well as other kidney diseases.

 

  • APOL1 genetic variants account for much of the excess risk of chronic and end stage kidney disease, which results in a significant global health disparity for persons of African ancestry.

 

  • In 2019, Vertex completed a Phase 1 clinical trial for VX-147, its first investigational oral small molecule medicine for the treatment of FSGS and other serious kidney diseases.
    • Phase 2 clinical trial to evaluate VX-147 is expected to begin in 2020.

 

  • Patients with pain can suffer from acute pain (for example, following surgery or an injury), neuropathic pain (when there is damage to a nerve), and musculoskeletal pain.

 

  • Current treatments may not work well or cause significant side effects. In addition, there is the potential for addiction and the practice of over- and mis-utilization, as well as underutilization of current pain medicines.
  • Vertex has discovered multiple inhibitors of the sodium channel 1.8, or NaV1.8, as potential treatments for pain.
    • Obtained positive results from three separate Phase 2 clinical trials evaluating VX-150, a NaV1.8 inhibitor, in patients with three different pain conditions: acute, neuropathic and musculoskeletal pain.
    • Opted to hold off on starting a late-phase trial of VX-150, choosing instead to gather data on the drug’s siblings before deciding which molecule to advance.
    • In the first quarter of 2020, announced the discontinuation of Phase 1 development of VX-961; expected to begin clinical development of an additional molecule in the first half of 2020.

 

  • Sickle Cell Disease and Beta-Thalassemia

 

  • Sickle cell disease is a group of disorders that affects haemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorder have atypical haemoglobin molecules called haemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.
    • Characteristic features of this disorder include a low number of red blood cells (anaemia), repeated infections, and periodic episodes of pain. The severity of symptoms varies from person to person. Some people have mild symptoms, while others are frequently hospitalized for more serious complications.

 

  • Beta thalassemia is a blood disorder that reduces the production of haemoglobin
    • In people with beta thalassemia, low levels of haemoglobin lead to a lack of oxygen in many parts of the body. Affected individuals also have a shortage of red blood cells (anaemia), which can cause pale skin, weakness, fatigue, and more serious complications. People with beta thalassemia are at an increased risk of developing abnormal blood clots.

 

  • Vertex is co-developing CTX001, an investigational gene-editing treatment, for the treatment of hemoglobinopathies, with CRISPR. A CRISPR/Cas9-based therapy to treat both beta-thalassemia and sickle cell disease.
    • In November 2019, the company announced positive, interim data from the first two patients with severe haemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy, CTX001, in ongoing Phase 1/2 clinical trials.

 

  • Type 1 Diabetes

 

  • Type 1 diabetes (T1D), once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin. Insulin is a hormone needed to allow sugar (glucose) to enter cells to produce energy.
    • Despite active research, type 1 diabetes has no cure. Treatment focuses on managing blood sugar levels with insulin, diet and lifestyle to prevent complications.

 

  • In 2019, Vertex acquired a preclinical program to develop cell-based therapies for T1D through the acquisition of Semma. The company plans to advance this program into clinical development in T1D patients in late 2020 or early 2021.

 

  • Duchenne Muscular Dystrophy

 

  • Duchenne muscular dystrophy (DMD) is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females. DMD causes progressive weakness and loss (atrophy) of skeletal and heart muscles.

 

  • Early signs of DMD may include delayed ability to sit, stand, or walk and difficulties learning to speak. Muscle weakness is usually noticeable by 3 or 4 years of age and begins in the hips, pelvic area, upper legs, and shoulders. The calves may be enlarged. Children with DMD may have an unusual walk and difficulty running, climbing stairs, and getting up from the floor.

 

  • In 2019, Vertex acquired preclinical programs to develop genetic therapies for DMD and DM1 through the acquisition of Exonics and the expansion of its collaboration with CRISPR.

 

Appendix I: Product Portfolio

Vertext Products

 

Appendix II: FDA Approval Process

 

FDA Approval Process

  • Clinical trials

 

  • Phase 1 uses 20 to 80 healthy volunteers to establish a drug’s safety and profile (about 1 year).

 

  • Phase 2 employs 100 to 300 patient volunteers to assess the drug’s effectiveness (about 2 years).

 

  • Phase 3 involves 1000 to 3000 patients in clinics and hospitals who are monitored carefully to determine effectiveness and identify adverse reactions (about 3 years).

 

Appendix II: Financial Summary and Consensus Estimates

Vertex FS

 

Vertex Consensus

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Charts & Ideas

“Life can only be understood backwards; but it must be lived forwards.” ― Søren Kierkegaard

This week’s piece comprises a few charts and ideas that stem from those charts.

Before getting to the charts, however, we want to address two unrelated points — the second may qualify as a rant.

1. The short-lived coupling of bonds and equities, where both asset classes sold off concomitantly, has been seen by some market participants and commentators as an indication of the market suddenly becoming acutely aware of the risk of rising inflation. Specifically, the broad-based fiscal and monetary measures being taken by governments and central banks leading to a sudden rise in inflation.

While we do consider the official measures being taken, to soften with economic blow from the COVID-19 pandemic, to be sowing the seeds of inflation at some hitherto unknown point in the future, we consider the recent sell-off in bonds to be indicative of:

  1. liquidation, where assets are sold off irrespective of price to meet investor redemptions and / or margin calls;
  2. foreign central banks and large pools of capital (e.g. pension funds and life insurers) monetising high quality assets to secure US dollars; and
  3. some level of profit taking by speculative accounts (e.g. hedge funds) after the sharp move lower in yields.

For as long as demand, specifically consumer demand, remains capped by the drastic measures being taken to “flatten the curve” and we do not reach a stage where demand far outstrips supply, we consider any discussion over fears of a sudden spike in inflation to be premature. Moreover, if the absence of demand, exacerbated by a shortage of US dollars, leads to a spiralling credit default cycle, the deflationary impulse in the global financial system will overpower any and all of the measures being taken by central banks and governments.

As we have said on a number of occasions, a deflationary bust is likely to precede runaway inflation.

Why?

A deflationary bust is what we think brings about the next big Lehman-like casualty amongst the global banking behemoths. In response to which the authorities would have to take unprecedented measures that devolve into a loss of confidence in the major currencies, namely the US dollar and / or the euro.

Do not position the core of your portfolio for rampant inflation or an end-of-fiat currencies type of regime change, at least not yet.

2. At times we hear or read commentators and market participants discussing the “foreseeable future”. For example, “the COVID-19 pandemic has changed the world for the foreseeable future” or “markets are likely to remain volatile for the foreseeable future”.

To that we ask: How much of the future is foreseeable exactly?

The only correct answers to the question are (a) none of it or (b) absolutely none of it.

Certain events are “foreseeable”, say sunset, and certain events are “highly probable”, such as a company with high levels of debt and generating negative free cash flow defaulting during a financial crisis. Even those are few and far between.

Pro-tip: Ignore any recommendations that are based on knowledge of the foreseeable future.

Rant over. On to the charts.

Charts & Ideas

Crude Oil Contango

Definitions:

Contango is the situation in which the spot or cash price of a commodity is lower than the forward price.

Backwardation is the situation in which the spot or cash price of a commodity is higher than the forward price.

1

The above chart is of the spread between the price per barrel of Brent crude due for delivery in six months from now and that due for delivery in the current month. When the line is above zero, crude oil is said to be in contango and when it is below zero it is said to be in backwardation.

Since OPEC and Russia instituted the policy of supply cuts to rebalance the oil market, the crude oil market was largely in backwardation. That is, immediate supply was (artificially) constrained and the market expected prices to fall once supply was reinstated.

With Saudi Arabia and Russia entering a price war and the price of crude collapsing, the current price is, according to oil market participants, not seen to be sustainable. Current prices are deemed too low to sustain for oil producers be it shale, Russia or Saudi Arabia. Hence, the market has gone into contango.

When a commodity market goes into contango, traders are motivated to hoard supply by buying in the current month and immediately lock in a profit by selling a for delivery futures contract for delivery at some future date. This is exactly what is happening in the oil market.

To hoard oil, traders are required to lease very large crude carriers (VLCCs) and store their oil on these vessels till such time that the delivery has to be made.

The economics of the trade are the spread between spot and future oil prices multiplied by the number of barrels stored for future delivery less the cost of leasing and operating the VLCC till delivery. (VLCCs are leased based on daily rates, unless chartered on long term contracts — something primarily reserved for oil companies and not traders.)

Based on some back of the envelope calculations, and subsequently confirming with shipping brokers, the rule of thumb is that a US dollar 1 spread between spot and the 6 months futures price supports a VLCC rate of roughly US dollars 10,000. That is, traders are willing to pay a daily lease rate of US dollars 10,000 per vessel for each dollar of spread between spot and the futures price.

The current spread as per the above chart is approximately US dollars 10. That should support daily VLCC rates of approximately US dollars 100,000. Depending on the shipping route, VLCC rates are currently averaging around US dollars 100,000 per day. To put that in context, over the last two decades, VLCC rates have averaged approximately US dollars 20,000 per day. Suffice to say, it is a good time to be an owner of a VLCC.

According to a shipping broker we spoke to:

“As long as Saudi keeps the pumps open and demand remains weak, this trend is likely to continue – we believe 15 to 20 VLCCs has been taken up for storage up until now.”

To play this theme, one should buy stocks such as Scorpio Tankers $STNG, Frontline Ltd $FRO and Teekay Tankers $TNK.

USA versus the Rest of the World

Last week we shared a chart of a proxy for the size of the Eurodollar banking system versus that of US money supply M2.  In the chart below, the magenta line is the ratio of US M2 to the Eurodollar proxy. While the yellow line is the ratio of the performance of the S&P 500 Index to the performance of the MSCI All Cap World ex. USA Index.

Until such time that we witness an easing of US dollar shortages in the rest of the world, there is little to no reason to prefer non-US markets to US markets, broadly speaking.

Consumer Staples to Consumer Discretionary

Last chart for this week.

3

The above chart is a ratio of the consumer staples index to that of the consumer discretionary index. A rising line implies that staples are outperforming discretionary consumer plays.

The last decade has come to be characterised to a certain degree by the growing disparity between the haves and the have nots, by wealth inequality. The rich are more likely to engage in conspicuous consumption. If you look at the consumer brands that have risen to new heights over the last decade — Apple, Lulu Lemon, Louis Vuitton and the brands under the LVMH umbrella, Peloton, etc. — they almost exclusively position themselves to appeal to the classes over the masses. That trend for now at least has been arrested — no one goes shopping for luxury bags when they are worried about catching a virus but everyone needs to eat, wash and clean.

For as long as the COVID-19 pandemic does not subside, we continue to prefer staples. Especially the ones with the most robust supply chains.

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Prescription then Description

Discussion on US dollar shortage.

 

“Everything is complicated; if that were not so, life and poetry and everything else would be a bore” — Wallace Stevens

 

A longer than usual piece. This may be one of the more important pieces of analysis we have issued. You can find a PDF version here, if you prefer.

 

The prescription first.

If you are in…

…Singapore, buy US dollars.

…the UK, buy US dollars.

…Australia, buy US dollars.

…Canada, buy US dollars.

…an emerging market, sell everything and buy US dollars.

And if you own gold, you probably do not own enough US dollars.

The prescription should be clear: Long USD.

 

At the start of the year, we wrote:

 

“Using $DXY as the guidepost, long US dollar below 95 versus the Australian dollar and New Zealand dollar, given the low cost of carry.”

 

The “below 95” call has been one of our better calls but not including more currencies was, in hindsight, short-sighted.

broad trade weighted USD.png

The above is the broad trade weight US dollar index, not $DXY, and it is breaking out.

 

Before we get to the description, we want share to two messages we received this week. One from the treasurer of a major British bank and the other from a member of the balance sheet management team at a major European bank.

 

“Despite the USD swap lines, top tier US bank paying 90bps above LIBOR for short date cash! LIBOR just set higher. Despite OIS going lower…And long-term USD FX swaps at 2% despite Fed cutting to zero.”

 

“[Name of bank] is in serious issues it has got margin calls left right.”

 

Lastly for the anecdotes, JP Morgan and Citi issued 10-, 20- and 30-year bonds this week priced with yields to maturity around 4 per cent. In contrast, just 10 days earlier, JP Morgan issued similar instruments with yields to maturity around 1.5 per cent.

 

The actions the Fed has taken thus far are not proving sufficient to overcome dislocations taking place in funding markets.

 

Eurodollars

 

To put things in the proper context, we first want to briefly touch upon the structure of global banking operations, specifically the Eurodollar market.

 

“The Euro-dollar market is the latest example of the mystifying quality of money creation to even the most sophisticated bankers, let alone other businessmen. Recently, I heard a high official of an international financial organization discuss the Euro-dollar market before a collection of high-powered international bankers. He estimated that Euro-dollar deposits totalled some $30 billion. He was then asked: “What is the source of these deposits” His answer was: partly, U.S. balance-of-payments deficits; partly, dollar reserves of non-U.S. central banks; partly the proceeds from the sale of Euro-dollar bonds.

 

This answer is almost complete nonsense. Balance-of-payments deficits do provide foreigners with claims on U.S. dollars. But there is nothing to assure that such claims will be held in the form of Euro-dollars. In any event, U.S. deficits, worldwide, have totalled less than $9 billion for the past five years, on a liquidity basis. Dollar holdings of non-U.S. central banks have fallen during the period of rapid rise in Euro-dollar deposits but by less than $5 billion. The dollars paid for Euro-bonds had themselves to come from somewhere and do not constitute an independent source. No matter how you try, you cannot get $30 billion from these sources. The answer give is precisely parallel to saying that the source of the $400 billion of deposits in U.S. banks (or for that matter the much larger total of all outstanding short-term claims) is the $60 billion of Federal Reserve credit outstanding. The correct answer for both Euro-dollars and liabilities of U.S. banks is that their major source is a bookkeeper’s pen.

 

[…]

 

Just what are Euro-dollars?

 

They are deposit liabilities, denominated in dollars, of banks outside the United States. Engaged in Euro-dollar business, for example, are foreign commercial banks such as the Bank of London and South America, Ltd., merchant banks such as Morgan Grenfell and Co., Ltd., and many of the foreign branches of U.S. commercial banks. Funds placed with these institutions may be owned by anyone-U.S. or foreign residents or citizens, individuals or corporations or governments. Euro-dollars have two basic characteristics: first they are short-term obligations to pay dollars; second, they are obligations of banking offices located outside the U.S. in principle, there is no hard and fast line between Euro-dollars and other dollar-denominated claims on non-U.S. institutions – just as there is none between claims in the U.S. that we call “money” and other short-term-claims. The precise line drawn in practice depends on the exact interpretation given to “short-term” and to “banks”.”

 

Excerpts from The Euro-Dollar Market: Some First Principles (1971) by Milton Freidman

 

Eurodollars, in layman terms, are unsecured bank deposits held at banks outside the US and therefore do not fall under the regulatory regime of the Federal Reserve or the US Government. They come into existence when (1) a domestic US bank transfers US dollar deposits to a foreign bank or branch or (2) a foreign bank creates a US dollar loan or buys a dollar-denominated security.

The Eurodollar system came into existence primarily to facilitate global trade and that remained its function up until the late 1990’s. Since the late 1990’s, however, Eurodollars have increasingly facilitated funding structures of domestic US bank and non-bank financial institutions (otherwise referred to as the shadow banking system).

 

If you are wondering what happened in late 1990’s to enable the transformation, it was the repeal of the Glass-Steagall Act, which in turn removed the regulatory barriers stopping Eurodollars to make their way back into the US.

 

Given the scale of the Eurodollar system, its transformation from a facilitator of global trade to a source of domestic funding in the US had a profound impact in asset markets — essentially, it enabled the tech and housing bubbles.

 

As an aside, when valuations metrics such as the cyclically adjusted price to earnings ratio, or CAPE, are used to compare markets today with long-term averages, they are much less meaningful for data prior to the late 1990’s given the non-stationarity of the data. That is, the transformation of the Eurodollar market essentially created different market regimes with very different dynamics — the pre-transformation regime was that of a scarcity of capital and the post-transformation regime became one with an abundance of capital. More capitals ergo higher valuations and tighter credit spreads.

 

Eurodollar.png

 

The above chart compares the external liabilities in foreign currencies of all sectors across all reporting countries (as reported by the Bank for International Settlements) versus the money supply M2 in the US. The former is a suitable proxy for the size of the Eurodollar system — one caveat is that the series comprises of all foreign currencies, given the reserve currency status of the greenback approximately 80-90% of series can be approximated to be Eurodollars, which is good enough for our analysis.

 

From the above, we can see the parabolic move higher in the size of the Eurodollar system starting in the late 1990’s. Second, following the Global Financial Crisis, we can see the stagnation of the growth in Eurodollars — the repeal of Glass Steagall Act unleashed the system, the introduction of Basel III and Dodd-Frank regulations has restrained it.

 

The stagnation of the growth in Eurodollars combined with the continued growth of money supply in the US points to why calls for a rotation out of US assets into non-US, particularly emerging market, assets have been incorrect. Since the Global Financial Crisis, global markets have undergone a regime change once again — this time dollar-denominated capital bifurcated: abundance in the US and scarcity everywhere else. This is why comparing the current relative valuations between non-US markets and US markets versus those from prior market regimes no longer provided a meaningful signal.

 

The US Dollar Squeeze

 

Global Trade

 

In mid-February we shared our notes from meetings with the a number of the leading multinational consumer packaged companies to understand the supply chain challenges caused by the breakout of the COVID-19 virus in China.

 

“[T]he suspension of Chinese manufacturing has revealed the deep-rooted interdependencies within global supply chains — much like the interdependencies between global financial institutions revealed by the Lehman bankruptcy. Given these interdependencies, it is no surprise that there is panic and investors are rushing into safe haven assets.”

 

One of the factors we overlooked at the time was how a collapse in trade would impact FX markets. What transpired was first a sharp decline in corporations’ need to drawdown trade finance facilities. This improved the liquidity situation at financial institutions engaged in trade finance. Since most trade is conducted in US dollars, this created a temporary abundance was dollar negative.

 

Following, the global spread of the COVID-19 virus, global markets start to crater. This is turn unleashed a vicious unwind of carry trades financed in euros, yen and the Swiss franc and contributed to a further weakening of the greenback.

 

These were the first order effects, to say.

 

 Secondary Effects

 

Next what followed were defaults, missed payments and reduced trade, which all of a sudden meant US dollar stopped flowing from debtors to creditors and Eurodollar creation has come to a screeching halt. Producing a shortage of US dollars at non-US financial institutions.

 

This shortage of US dollars is now starting to prompt central banks, without swap lines with the Fed, to (a) monetise dollar-denominated securities or (2) to drawdown their foreign reserves from accounts in London, Hong Kong and other financial centres, to make hard currency available to their domestic banks.

 

This has increased the supply of Treasury securities and corporate bonds in the market and government bonds have sold-off concomitantly with stocks — when government bonds stop serving as a hedge, the pain felt by real money investors increases exponentially.

 

Then, the Fed by cutting interest rates to zero caused capital out of money market funds and in bonds, where there was still yield to be had. US banks and US branches of foreign banks utilise money market funds as a source of dollar funding. Money market funds are also where commercial paper is financed. The flow out of money market funds has exacerbated the dollar shortage and reduced the availability of funding for corporations at the very moment they need it most.

 

The Fed announcing late Wednesday it is establishing a special backstop for money market mutual funds comes as no surprise.

 

Large corporations (Boeing, AerCap Holdings, etc.) are drawing down their unutilised credit facilities just in case they need the funds and / or the facilities are cancelled. This too is placing stress on bank balance sheets.

 

Deposits and Regulatory Implications

 

Deposits from non-financial corporations are, in regulatory terms (i.e. risk-weighted cost and liquid coverage requirements), the most efficient form of funding for financial institutions.

 

While commercial activity has markedly slowed down, corporations still have to bear fixed costs (rent, salaries, etc.). Consequently, companies are now drawing down deposits without replenishing them with increased revenue. This is further reducing the amount of funding available to banks. Moreover, banks are having to replace low cost funding with more expensive sources funding.

 

Banks are being squeezed from all angles and the more painful it gets for them, the higher the US dollar will go. There is only one portfolio hedge today and that is the greenback. Embrace it.

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Ideas, Unintended Consequences & Not A Regular Demand Shock

 

“History is a cyclic poem written by time upon the memories of man” — Percy Bysshe Shelley

 

Prior to the Global Financial Crisis, Australia, unlike many other developed nations such as the US and UK, did not have a deposit insurance scheme in place. At the height of the crisis in 2008, the Reserve Bank of Australia (RBA) fearing a run on any one of the Australian banks introduced the Financial Claims Scheme (FCS), under which the Australian Government guarantees the timely repayment of deposits up to a predefined cap.

 

The RBA’s intention with the introduction of the FCS was to get ahead of a potential destabilisation of the Australian banking system. What the RBA did not take into consideration was that because deposits were not insured, Australian depositors kept a higher portion of their assets — as compared to global averages — in money market funds to take advantage of the higher returns.

 

The introduction of the FCS meant, however, that deposits were insured while assets held in money market funds were not. During a crisis, given people’s preferences to avoid losses, there was a rush for the exits from Australian money market funds and into bank deposits. A vicious cycle ensued, the outflow of capital from money market funds made them riskier, which led to even more withdrawals, and so forth.

 

Within four days of the introduction of the FCS, money market funds in Australia were frozen by the RBA. Millions of retirees who relied on withdrawals from money markets to pay for food, housing, and other essential items could no longer afford basic necessities.

 

“The principles governing the behaviour of systems are not widely understood” — Jay Wright Forrester

 

With the global spread of the COVID-19 virus, all manners of policies are being introduced the world over. Whether it is Saudi Arabia and Russia starting an oil price war, President Trump halting inbound flights from Continental Europe, the Federal Reserve making vast sums of short-term loans available on Wall Street and committing to purchase Treasury securities, or Italian clinics and hospitals turning away elderly patients to focus on younger patients that statistically have a higher probability of surviving.

 

One or more of such policies enacted under pressure is bound to lead to unintended consequences. We just do not know what they will be.

 

 

Not A Regular Demand Shock

 

With policymakers the world over flailing desperately — and unsuccessfully — for an effective response to the COVID-19 pandemic, financial markets are now in full-blown panic mode. Corporate credit spreads have gapped to recession-like levels, valuation do not seem to matter, and all backward-looking and even coincident economic data points are useless. Uncertainty reigns supreme.

 

The question now is, what will stop the rot?

 

Two weeks ago, we wrote:

 

Governments will most likely have to introduce some form of fiscal stimulus to counter the global slow down. Fiscal stimulus, we think is unlikely to be instituted, until and unless monetary policy has been loosened to the extent that it (a) cannot be loosened further or (b) proves impotent.

 

The Fed’s 50 basis point interest rate cut has proven impotent. The Fed’s assurances that it would pump trillions of dollars into the financial system to ease stresses in short-term funding and US Treasury markets also failed to stop the rot.

 

The reason is simple, the global economy is suffering from a demand shock and the measures being taken or bandied about are supply-side measure. A demand-side problem cannot be solved using supply-side policies.

 

The below is a diagram from The Holy Grail of Macroeconomics: Lessons from Japan’s Great Recession written by Mr Richard Koo, Chief Economist at Nomura Research Institute. We have shared it in the past, we think it is worth sharing again.

 

Yin yang

 

Rather than monetary policy pricking the bubble in stage (1), this time we have had a global pandemic. It is only a matter of time before companies start focusing on debt minimisation (stage 3) as demand for (most) products and services has fallen off a cliff. In stage (3), monetary policy stops working. Government’s must stimulate demand by through fiscal measures.

 

We think a fiscal stimulus is almost given. A question of if not when.

 

What is different, however, about the demand shock this time around is that it has coincided with large-scale shuttering of supply. Unlike in prior crises, when production continues despite a lack of demand. This time around the situation will not be exacerbated by high levels of inventory, rather inventory levels are already too low. Therefore, if governments act to deliver fiscal stimulus and the pandemic subsides, the global economy could be in for a positive demand shock and a much swifter recovery than anyone expects.

 

We assign a much greater probability to such a scenario than most.

 

Trade Ideas

 

We have not sent out trade ideas for some time. This is because we have been unable to identify anything resembling a decent opportunity and prefer not to recommend shorts as drastic times can result in policymakers enacting short-sale bans.

 

As we head into this weekend, however, we think, for those with the stomach for a little risk, there is a case to put some money to work today. This can be done through a broad-based exposure by buying an ETF such as $SPY, a long in some of the very oversold energy names such as Occidental $OXY, or longs in high quality technology plays ($MSFT, $FB). One of the names from our open trade ideas we like adding to here is Slack Technologies $WORK.

 

Please note a number of our previous ideas have hit their stop losses, we have not sent out emails for those but directly added closed trades to our track record page.

 

Thank you for reading!

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guarantee

 

 

Supply & Undoing Globalisation

 

An email exchange with a friend and former colleague of ours reminded us of Capital Returns: Investing Through the Capital Cycle: A Money Manager’s Reports 2002-15 — a book comprised of edited versions of reports issued by London-based Marathon Asset Management.

Marathon’s investment approach is driven by avoiding investing in sectors, or markets, where investment spending is unduly elevated and competition is fierce, and to put one’s money to work where capital expenditure is depressed, competitive conditions are more favourable and, as a result, prospective investment returns are higher. Simply put, Marathon seeks out sectors where supply is or is likely to become constrained and avoids sectors where supply is likely to increase sharply in the near to medium-term.

The focus on supply over demand, Marathon argues, is because supply is easier to measure and predict than as compared to demand. The following passage from the book, we think, captures, the manager’s investment framework.

 

“The key to the ‘capital cycle’ approach – the term Marathon uses to describe its investment analysis – is to understand how changes in the amount of capital employed within an industry are likely to impact upon future returns. Or put another way, capital cycle analysis looks at how the competitive position of a company is affected by changes in the industry’s supply side.”

 

This got us to thinking about where is or could supply be potentially constrained. We could not come up with much. The list of oversupplied markets in the world today is seemingly endless. Just consider the following:

 

  1. OPEC and other oil producing nations have gone to great lengths to curtail supply of crude and push up spot prices. Even then prices remain moribund — supply from the shale patch in the US just keeps surprising to the upside, overwhelming any robustness in demand.

 

  1. Kazatomprom and Cameco, the two largest uranium mining companies globally, have shuttered significant portions of their supply to prop up uranium prices. Prices though remain near the lower bound and the supply cuts have neither made a lasting impact on prices or on buyers.

 

  1. An estimated 1.3 billion tonnes of food is wasted globally each year, one third of all food produced for human consumption, according to the Food and Agriculture Organization (FAO) of the United Nations.

 

  1. Industry forecasts indicate that steel oversupply in China is expected to rise to 196 million tonnes in 2020, up 13 per cent from 174 million tonnes estimated in 2019.

 

As we were considering the above, we came across the following passage in a recent issue of Ben Thompson’s Stratechery Newsletter (emphasis added):

 

“[I]f you are going to take advantage of the Internet transforming one part of the value chain, you had best ensure you are anticipating the transformations in the other parts as well. And, on the flipside, in a world of abundance being able to aggregate demand is more valuable than being able to create supply; it may offend our analog sensibilities that 90 million email addresses are more valuable than real-world factories, but such is the transformative nature of the Internet.

 

Marathon’s approach of focusing on supply made sense in a world dominated by physical products and real-world constraints. Today, the top-five companies in the world by market capitalisation are:

 

  1. Microsoft
  2. Apple
  3. Amazon
  4. Alphabet (Google)
  5. Facebook

 

Other than Apple, none are constrained — at least, as far as their primary businesses are concerned — by supply.

In a world dominated by companies with infinite supply, the key analytical skill in recent years has not been the ability to model supply but rather being able to identify the companies that will best aggregate demand. Machines, with their ability to process big data in near real time, are better placed to understand and determine demand than humans, which may in some part explain the continued under performance of non-systematic, discretionary investment strategies.

 

Undoing Globalisation

The global spread of the Covid-19 virus is acting as a propellant on the anti-globalisation trend which has been unfolding since the Brexit referendum and the election of President Trump. The shift in attitude toward China and the lack of resilience shown by globally integrated supply chains optimized for profits is likely to lead to a new kind of investment environment.

The kind of investment environment where there continue to be aggregators, especially in technology related sectors, but there is a shift in the supply dynamics of ‘old economy’ sectors where figuring out supply once again becomes a source of alpha.

We highlight two further changes in the investment environment that may arise as the trend toward de-globalisation accelerates.

 

#1 Capital Expenditures over Buybacks

Much has been written about buybacks, some of it good and some just utter tosh.

Irrespective of one’s view on buybacks, it is easy to understand their appeal at a time when supply is not a concern. Rather than investing excess cash into property, plant and equipment, companies have been, following the Global Financial Crisis, been incentivised to pursue buybacks — the return on investment on buybacks a priori has simply been superior.

As companies look to move supply chains from China and potentially insource critical manufacturing functions, capital expenditures will be prioritised over buybacks. Companies that move first and fastest are likely to be the ones rewarded and the laggards punished.

 

#2 The Chinese Consumer’s Importance to Rise

Supply chains in China will not be entirely dismantled — China is after all the second biggest single market after the US for most multinational companies and a population of 1.3 billion has to be catered for.

What we envisage is the Chinese leadership finally taking meaningful steps to move away from its (unsustainable) investment led growth model and transforming its economy to be consumption led. This shift is necessary to reduce the need to mothball large parts of the industrial infrastructure on the Mainland.

Such a shift in China’s growth model, however, is unlikely to manifest without tectonic shifts in global foreign exchange markets — is the US dollar index $DXY after almost touching 100 then falling below 97 sniffing this out? It is difficult to say but that is a discussion for another day!

Thank you for reading!

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.

Duration

 

“Knowing reality means constructing systems of transformations that correspond, more or less adequately, to reality.” — Jean Piaget

“We’ve got facts, they say. But facts aren’t everything, at least half the battle consists in how one makes use of them!” — Crime and Punishment, Fyodor Dostoyersky

 

A short one this week.

The formal definition first.

Duration is a measure of the sensitivity of the price of a bond (or more accurately, any financial instrument) to a change in interest rates. Duration is non-linear and accelerates as time to maturity diminishes, i.e. financial instruments become less sensitive to changes in interest rates as maturity draws closer.

 

Duration: Now What?

 

At the start of the year, we advised “Using rallies to reduce equity exposures tactically and increase bond allocations”. This prescription was based on our assessment of the lay of the land prior to the global spread of Covid-19.

The coronavirus has hastened the rush into safe haven assets, pushing 10-year US Treasury yields to all-time lows — 1.2 per cent is the most recent print. Notably, the other safe haven asset, German 10-year bunds, has also followed suit. At the same time, global equity markets are on track to have their worst week since the Global Financial Crisis.

Picture1.png

 

The global spread of the Covid-19 virus has revealed the glaring fragility of the globalised world we live in. As discussed last week, the suspension of Chinese manufacturing has revealed the deep rooted interdependencies within global supply chains — much like the interdependencies between global financial institutions revealed by the Lehman bankruptcy. Given these interdependencies, it is no surprise that there is panic and investors are rushing into safe haven assets.

The corollary of the rush into safe haven assets is that pension managers, already facing an asset-liability duration mismatch, are forced into buying ever more bonds as long-term yields decline. This need to buy an increasing amount of bonds, precipitates a vicious feedback loop — increasing demand for bonds begets further demand for bonds, pushing yields lower and lower. Making bonds the ultimate momentum trade.

It may only be a matter of time before we see a US 10-year yield print with a 0 in front of it.

The long-end is not the only part of the yield curve where the action is. According to The Wall Street Journal:

 

Federal-funds futures, which traders use to bet on the path of central-bank policy, showed Thursday afternoon that investors thought there was a 72% chance the Fed will lower its key policy rate by a quarter-percentage point at its March 17-18 meeting, according to CME Group data. That was up from just 9% a week ago,

 

Investors also saw an 83% chance the Fed will cut rates by at least 0.50 percentage point by the end of its July meeting and a 46% chance it will cut rates 0.75 percentage point by that time.

 

Markets are pricing in short-term US rates heading toward the zero-bound once again. The Fed, publicly at least, is not yet entertaining the need to further ease monetary policy.

In a speech Tuesday, Fed Vice Chairman Richard Clarida said disruptions from the viral outbreak in China “could spill over to the rest of the global economy” but that it is too soon to “even speculate about either the size or the persistence of these effects, or whether they will lead to a material change in the outlook.”

History has shown that once the market starts pricing in rate cuts, it is only a matter of time before the Fed follows through. The longer the Fed fails to communicate as much, the lower the equity markets will go.

 

It is not a Monetary Policy Issue

 

The argument against the Fed, or any other major central bank, easing policy is that the global spread of the Covid-19 is not a monetary policy issue. That is, looser monetary policy will not remedy the forced slowdown in global economic activity.

That is true. Governments will most likely have to introduce some form of fiscal stimulus to counter the lobal slow down. Fiscal stimulus, we think is unlikely to be instituted, until and unless monetary policy has been loosened to the extent that it (a) cannot be loosened further or (b) proves impotent.

 

The Contrarian View: Not Just Keeping Powder Dry

 

The global economic slowdown is priced in. A sell-off in equity markets is warranted. The question, as always is, how to position for that which is not priced in.

The last decade witnessed long-duration assets, with stable and almost annuity-like cash flows, being bid-up. Be it developed market bonds, corporate credit, technology companies such as the FANGs, software stocks with subscriptions-like revenues and consumer packaged goods companies such as Procter & Gamble.

With equities falling out of favour in the interim and long-term rates collapsing, we think the market is being primed for an almighty rally in stocks with long-duration like attributes. This view is predicated on (1) a vaccine for Covid-19 being found and (2) the Fed easing monetary policy.

Till such time we recommend keeping most of your powder dry and gradually adding high quality technology companies (such as Facebook) to your portfolios. Once the above conditions are met, there may even be room to jump into beaten-up cyclical sectors — energy, industrials and materials.

 

Thank you for reading!

 

This post should not be considered as investment advice or a recommendation to purchase any particular security, strategy or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.